Clinical Trials Directory

Trials / Conditions / Migraine With or Without Aura

Migraine With or Without Aura

21 registered clinical trials studyying Migraine With or Without Aura2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
NCT07497854
Pfizer
CompletedEvaluation of a Wearable Device for Acute Treatment of Migraines
NCT07015125
Hinge Health, IncN/A
CompletedCooling to Alleviate Migraine #3
NCT06874361
Mi-Helper, Inc.N/A
RecruitingNew Methods for Evaluating Preventive Migraine Treatment
NCT07071506
University of AarhusN/A
Active Not RecruitingExploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: A Si
NCT06695156
Maharishi International UniversityN/A
CompletedTrial in Adult Subjects With Acute Migraines
NCT03461757
PfizerPhase 3
CompletedOpen Label Safety Study in Acute Treatment of Migraine
NCT03266588
PfizerPhase 2 / Phase 3
CompletedThe Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
NCT03194555
Allodynic Therapeutics, IncPhase 2
CompletedSafety and Efficacy in Adult Subjects With Acute Migraines
NCT03237845
PfizerPhase 3
CompletedSafety and Efficacy Study in Adult Subjects With Acute Migraines
NCT03235479
PfizerPhase 3
CompletedAn Acute Migraine Factorial Study
NCT06245902
Allodynic Therapeutics, IncPhase 2
CompletedLow-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
NCT03061734
Allodynic Therapeutics, IncPhase 2
CompletedAn Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migrain
NCT02873221
AllerganPhase 3
CompletedEfficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migr
NCT02848326
AllerganPhase 2 / Phase 3
CompletedEfficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02867709
AllerganPhase 3
CompletedEfficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02828020
AllerganPhase 3
CompletedThree Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
NCT02605174
Eli Lilly and CompanyPhase 3
CompletedEletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatrip
NCT01989936
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 3
CompletedComparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
NCT01986270
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 3
CompletedEletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
NCT01986088
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 3
CompletedEfficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
NCT01978496
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 3